Medicenna Therapeutics 

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops bizaxofusp (MDNA55), an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a masked bi-functional anti-PD1-IL2 Superkine for various solid tumors; and MDNA132, an IL-13 Superkine for various tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, inhibitors, antibodies, cytokines, or other Superkines Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.